Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors

Abstract

This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently:—O —C(═O)— or —C(═O)—O — or —C(═O)—; Cy is a cyclyl group and is independently: Ccarbocyclyl, Cheterocyclyl, or Caryl; and is optionally substituted; Qis a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having fromtoring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having fromtoring atoms includingnitrogen ring atom oroxygen ring atom; and is optionally substituted; Qis an acid leader group, and is independently: Calkylene; and is optionally substituted; or: Qis an acid leader group, and is independently: Carylene; Carylene-Calkylene; Calkylene-Carylene; or Calkylene-CaryleneCalkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.